Premium
Subcutaneous meloxicam suspension pharmacokinetics in mice and dose considerations for postoperative analgesia
Author(s) -
Chen Patty H.,
Boyd Kelli L.,
Fickle Erin K.,
Locuson Charles W.
Publication year - 2016
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/jvp.12297
Subject(s) - meloxicam , cyclooxygenase , pharmacokinetics , pharmacology , plasma concentration , medicine , anesthesia , chemistry , enzyme , biochemistry
Meloxicam is a cyclooxygenase ( COX ) inhibitor with a higher selectivity for cyclooxygenase‐2 ( COX ‐2) than for cyclooxygenase‐1 ( COX ‐1). In the laboratory setting, this nonsteroidal anti‐inflammatory drug ( NSAID ) is commonly selected for analgesia in mice and administered every 24 h. This study characterizes the plasma concentration achieved from a dose of 1.6 mg/kg of meloxicam administered once every 24 h subcutaneously for 72 h in male and female C57 BL /6 mice. These values were compared, over time, to reference COX ‐2 inhibition constants for meloxicam. No significant differences in trough plasma concentrations were noted between genders. The plasma concentrations were below the COX ‐2 IC 50 after 12 h. To maintain a plasma concentration at or above the COX ‐2 whole blood IC 50, the study results suggest an administration frequency of every 12 h when using a dose of 1.6 mg/kg in C57 BL /6 mice.